[go: up one dir, main page]

SG11202106116QA - Methods of producing polypeptides using a cell line resistant to apoptosis - Google Patents

Methods of producing polypeptides using a cell line resistant to apoptosis

Info

Publication number
SG11202106116QA
SG11202106116QA SG11202106116QA SG11202106116QA SG11202106116QA SG 11202106116Q A SG11202106116Q A SG 11202106116QA SG 11202106116Q A SG11202106116Q A SG 11202106116QA SG 11202106116Q A SG11202106116Q A SG 11202106116QA SG 11202106116Q A SG11202106116Q A SG 11202106116QA
Authority
SG
Singapore
Prior art keywords
apoptosis
methods
cell line
producing polypeptides
line resistant
Prior art date
Application number
SG11202106116QA
Inventor
Tia Alexandra Arena
Athena W Wong
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of SG11202106116QA publication Critical patent/SG11202106116QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2511/00—Cells for large scale production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11202106116QA 2018-12-21 2019-12-19 Methods of producing polypeptides using a cell line resistant to apoptosis SG11202106116QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862784051P 2018-12-21 2018-12-21
PCT/US2019/067455 WO2020132231A1 (en) 2018-12-21 2019-12-19 Methods of producing polypeptides using a cell line resistant to apoptosis

Publications (1)

Publication Number Publication Date
SG11202106116QA true SG11202106116QA (en) 2021-07-29

Family

ID=69182705

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202106116QA SG11202106116QA (en) 2018-12-21 2019-12-19 Methods of producing polypeptides using a cell line resistant to apoptosis

Country Status (11)

Country Link
US (1) US20210317501A1 (en)
EP (1) EP3898984A1 (en)
JP (1) JP7560459B2 (en)
KR (1) KR20210107025A (en)
CN (1) CN113631714A (en)
AU (1) AU2019403313A1 (en)
CA (1) CA3121804A1 (en)
IL (1) IL284148A (en)
SG (1) SG11202106116QA (en)
TW (1) TWI851632B (en)
WO (1) WO2020132231A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2022149607A1 (en) * 2021-01-07 2022-07-14
WO2024233529A2 (en) * 2023-05-07 2024-11-14 Regenxbio Inc. Compositions and methods for recombinant aav production
CN118516313B (en) * 2024-07-22 2024-11-05 上海奥浦迈生物科技股份有限公司 A BAX gene knockout 293F cell line and its application

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3883899T3 (en) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. CHANGED ANTIBODIES.
DE68925971T2 (en) 1988-09-23 1996-09-05 Cetus Oncology Corp CELL GROWING MEDIUM FOR INCREASED CELL GROWTH, FOR INCREASING LONGEVITY AND EXPRESSION OF PRODUCTS
ATE102631T1 (en) 1988-11-11 1994-03-15 Medical Res Council CLONING OF IMMUNOGLOBULIN SEQUENCES FROM THE VARIABLE DOMAINS.
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
FI941572A7 (en) 1991-10-07 1994-05-27 Oncologix Inc Combination and method of use of anti-erbB-2 monoclonal antibodies
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE69334255D1 (en) 1992-02-06 2009-02-12 Novartis Vaccines & Diagnostic Marker for cancer and biosynthetic binding protein for it
DE69303494T2 (en) 1992-11-13 1997-01-16 Idec Pharma Corp THERAPEUTIC USE OF CHIMERIC AND LABELED ANTIBODIES AGAINST HUMAN B LYMPHOCYTIC LIMITED DIFFERENTIATION ANTIQUES FOR THE TREATMENT OF B CELL LYMPHOMA
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
BR9813365A (en) 1997-12-05 2004-06-15 Scripps Research Inst Method for Production and Humanization of a Mouse Monoclonal Antibody
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
PT1068241E (en) 1998-04-02 2007-11-19 Genentech Inc Antibody variants and fragments thereof
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR101077001B1 (en) 1999-01-15 2011-10-26 제넨테크, 인크. Polypeptide Variants with Altered Effector Function
CA2393869A1 (en) 1999-12-15 2001-06-21 Genetech,Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
CA2488441C (en) 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
CN103833854B (en) 2002-12-16 2017-12-12 健泰科生物技术公司 Immunoglobulin variants and application thereof
US20050079574A1 (en) 2003-01-16 2005-04-14 Genentech, Inc. Synthetic antibody phage libraries
MXPA06011199A (en) 2004-03-31 2007-04-16 Genentech Inc Humanized anti-tgf-beta antibodies.
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
WO2005100402A1 (en) 2004-04-13 2005-10-27 F.Hoffmann-La Roche Ag Anti-p-selectin antibodies
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
WO2007056441A2 (en) 2005-11-07 2007-05-18 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
WO2007064919A2 (en) 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
AR060871A1 (en) 2006-05-09 2008-07-16 Genentech Inc UNION OF POLYPEPTIDES WITH OPTIMIZED SUPERCONTIGES
CN100592373C (en) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 Liquid crystal display panel driving device and driving method thereof
EP2294191B1 (en) * 2008-06-10 2016-09-28 Sangamo BioSciences, Inc. Methods and compositions for generation of bax- and bak-deficient cell lines
ES2609860T3 (en) * 2011-10-28 2017-04-24 The University Of North Carolina At Chapel Hill Cell line for the production of adeno-associated virus
JP6695814B2 (en) * 2014-06-04 2020-05-20 アムジエン・インコーポレーテツド Methods for harvesting mammalian cell cultures
CN106480090B (en) * 2016-10-08 2020-05-12 杭州电子科技大学 Transgenic vector system for promoting cell transplantation and gene expression and application thereof
PT3630977T (en) * 2017-06-02 2024-04-24 Ambrx Inc Methods and compositions for promoting non-natural amino acid-containing protein production

Also Published As

Publication number Publication date
TW202039853A (en) 2020-11-01
CA3121804A1 (en) 2020-06-25
JP7560459B2 (en) 2024-10-02
EP3898984A1 (en) 2021-10-27
US20210317501A1 (en) 2021-10-14
JP2022514082A (en) 2022-02-09
AU2019403313A1 (en) 2021-07-15
KR20210107025A (en) 2021-08-31
TWI851632B (en) 2024-08-11
WO2020132231A1 (en) 2020-06-25
IL284148A (en) 2021-08-31
CN113631714A (en) 2021-11-09

Similar Documents

Publication Publication Date Title
IL284148A (en) Methods of producing polypeptides using a cell line resistant to apoptosis
ZA201605926B (en) Conversion of a firearm to a firearm simulator
GB201602061D0 (en) A diaphragm type electrolytic cell and a process for the production of hydrogen from unipolar electrolysis of water
SG11202009329RA (en) Production of lithium hexafluorophosphate
PL3114258T3 (en) Passivation of micro-discontinuous chromium deposited from a trivalent electrolyte
ZA201707477B (en) Methods for assesing the purity of a mesenchymal stem cells preparation
SG11201503161PA (en) Production of a polycarbonate with limited metal residuals
GB201911958D0 (en) Methods of t cell production
PL3144282T3 (en) Methods of melting feedstock using a submerged combustion melter
GB201721657D0 (en) Digital to analogue conversion
EP3790667A4 (en) CARBON-BASED DIRECT PLATING PROCESS
GB201810534D0 (en) Hydrogen production
GB201802421D0 (en) Improvements relating to floating structures
MA40435A (en) Stay green cucumber plant
NO20180709A1 (en) A floating production unit
EP3601638C0 (en) ELECTROLYSIS CELL FOR HYDROGEN PRODUCTION
GB2584544B (en) Improvements to letter-plates
SG11202101999YA (en) Sodium bicarbonate production
GB201915803D0 (en) Cell production
GB2579284B (en) Improvements to a portable toilet
GB201807469D0 (en) Electrochemical production of hrydrogen from sea water
IL261145B (en) A technique for activating sulfur-based electrode for an electrolyser
GB2527509B (en) Improvements relating to a mechanically lined pipe
EP3241927A4 (en) Cover for an electrolysis cell for producing aluminium
SG11201703062VA (en) Process to prepare a composite ionic liquid